Kanghui Pharmaceutical(603139)2025-01-17 09:05Financial Performance - The company expects a net loss of approximately CNY 85 million for the fiscal year 2024, attributed to various operational challenges[2] - The estimated net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be around CNY 82 million in loss for 2024[4] - In the same period last year, the company reported a net loss of CNY 26.16 million, indicating a worsening financial situation year-over-year[5] Operational Challenges - The increase in fixed asset depreciation and bank loan interest expenses due to the establishment of a new production base and R&D center significantly impacted the current period's performance[7] - The company recognized an investment loss and bad debt provision of approximately CNY 16 million due to a lawsuit against Hubei Kelawei Biopharmaceutical Co., Ltd. for unpaid equity repurchase funds[7] - The company’s subsidiary, Shaanxi Youbang Biopharmaceutical Technology Co., Ltd., faced challenges in meeting performance commitments, leading to operational adjustments and continued losses[7] Financial Reporting and Risks - The financial data provided is preliminary and has not been audited by an external accounting firm, emphasizing the need for caution among investors[8] - The company warns of potential risks associated with the accuracy of the preliminary financial forecasts due to the lack of significant uncertainties affecting the forecast[8] - The final audited financial results for 2024 will be disclosed in the company's annual report, which will provide more accurate data[9] - The company emphasizes the importance of investor awareness regarding the risks associated with the preliminary earnings forecast[9]